Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQHJ | ISIN: US7612273059 | Ticker-Symbol:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
RESPIRERX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
RESPIRERX PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur RESPIRERX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury47Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx"or the"Company"), focused on the discovery and development of innovative and...
► Artikel lesen
13.02.RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine179Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and...
► Artikel lesen
02.02.RespireRx Pharmaceuticals Inc. - 8-K, Current Report1
22.01.RespireRx Pharmaceuticals Inc. - 8-K, Current Report1
22.01.RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors1
04.01.RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient170Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and...
► Artikel lesen
11.12.23RespireRx Pharmaceuticals Inc. - 8-K, Current Report1
11.12.23RespireRX Pharmaceuticals Inc.: RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development191Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx" or the "Company"), a biopharmaceutical company focused on the discovery and development...
► Artikel lesen
17.11.23RespireRx Pharmaceuticals Inc. - 10-Q, Quarterly Report2
14.11.23RespireRx Pharmaceuticals Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB-
12.10.23RespireRx, Ab Initio Partner on Dronabinol Manufacturing1
12.10.23RespireRx Pharmaceuticals Inc. - 8-K, Current Report1
12.10.23RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services1
02.10.23RespireRx Pharmaceuticals Inc. - 8-K, Current Report1
09.08.23RespireRX Pharmaceuticals Inc.: RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company212Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) ("RespireRx"), focused on the discovery and development of innovative and revolutionary treatments...
► Artikel lesen
24.05.23RespireRX Pharmaceuticals Inc.: ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs249Glen Rock, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) ("RespireRx") and ResolutionRx Ltd ("ResolutionRx"), collectively "RespireRx" and its subsidiaries...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1